Identification of Endothelial Cells and Progenitor Cell Subsets in Human Peripheral Blood

Abstract

An assay for circulating cell subsets in human peripheral blood by flow cytometry is used as a biomarker to determine cardiovascular disease risk and tumor responsiveness to chemotherapy since endothelial progenitor cells (EPCs) function in vasculogenesis and angiogenesis. Despite analytical advances in polychromatic flow cytometry (PFC), conventional approaches are routinely utilized to enumerate and isolate EPCs, which has led to varied results in clinical studies, potential cellular misidentification, and thus a lack of a plausible biological explanation for how purported EPCs function. Herein, a reproducible PFC protocol is provided to identify a rare circulating endothelial colony‐forming cell (ECFC) with proliferative potential, along with a population of circulating progenitor cells (CPCs) in which the ratio analysis distinguishes between healthy and disease populations. In sum, a reliable PFC protocol, which can be used to investigate the roles of human hematopoietic and endothelial elements in the growth and maintenance of the vasculature, is described. Curr. Protoc. Cytom. 52:9.33.1‐9.33.11. © 2010 by John Wiley & Sons, Inc.

Endothelial Progenitor Cell Homing Decreases Postoperative Complications in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass

“…Therefore, 138 patients were included in the study. for dead cells (15)(16)(17). Data acquisition was performed on a FACS Aria cytometer equipped with FACS Diva 5.0 software (BD) and analyzed by Flowjo software (Tree Star).…”

“…A minimum of 5,000, 000 events was acquired. The boundary between positive and negative cells was placed using fluorescence-minus-one controls and an internal control (16,17). Figure 1 illustrates the sequential gating strategy to mark EPCs for in-…”

Circulating Endothelial Progenitors and Bone Marrow Derived Cells as Biomarkers for Risk of Bronchopulmonary Dysplasia

“…Timmermans et al concluded that true EPCs (EOCs) from human blood are CD34+CD45-CD133-VEGFR-2+ (both CD133 negative and CD45 negative), whereas CD34+CD45+CD133+VEGFR-2+ cells are early outgrowth EPCs of hematopoietic origin [25]. In a multi-color flow cytometry protocol for identifying EPC, Estes et al, distinguishes between early EPCs of hematopoietic lineage, which are CD45 positive, and true EPCs (referred to as "ECFCs"), which are CD45 negative [29].…”

Perioperative Implications of Vascular Endothelial Dysfunction: Current Understanding of this Critical Sensor-Effector Organ

“…These cells may be recruited to denuded vessels in ischemic sites, but they do not directly become persistent vascular endothelial cells or display de novo in vivo vasculogenic potential. Rather, they display potent paracrine properties regulating new vessel formation via angiogenesis [73,74]. Yoder et al [33,64,75] refer to these cells as proangiogenic hematopoietic cells.…”